Repositive expands preclinical cancer model offering
Repostive expanded its cancer models offering to include cell-line derived xenograft (CDX) models, syngeneic, and humanized mouse models.
Repostive expanded its cancer models offering to include cell-line derived xenograft (CDX) models, syngeneic, and humanized mouse models.
Adhera Therapeutics has selected Iqvia’s Orchestrated Customer Engagement (OCE) technology platform to build its commercial infrastructure.
EMA’s CHMP gives positive opinion on treatment for sleeping sickness developed by Sanofi and DNDi, after the rediscovery of lead compound.
The US company will complete a ‘large-scale’ manufacturing facility to support production in the next three to five years.
The Indian firm is relocating manufacturing operations in New Jersey, from its Cranbury facility to New Brunswick, in an effort to “improve cost efficiencies” across the US.
Q&A
Swallowability is a recognised and growing patient problem, according to Colorcon’s general manager of film coatings, Kelly Boyer.